| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| VistaGen Therapeutics, Inc. | PRES./CHIEF SCIENTIFIC OFFICER | Common Stock | 64,958 | $111,533 | $1.72 | 31 Dec 2021 | Direct |
| VistaGen Therapeutics, Inc. | PRES./CHIEF SCIENTIFIC OFFICER | Common Stock | 33,901 | $58,208 | $1.72 | 31 Dec 2021 | By H. Ralph Snodgrass Living Trust, dated 10/2/2008 |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| VTGN | VistaGen Therapeutics, Inc. | 31 Dec 2021 | 1 | +$6,005 | 4 | PRES./CHIEF SCIENTIFIC OFFICER | 03 Jan 2022, 15:19 |
| VTGN | VistaGen Therapeutics, Inc. | 23 Aug 2021 | 2 | $0 | 4 | PRES./CHIEF SCIENTIFIC OFFICER | 03 Sep 2021, 16:19 |
| VTGN | VistaGen Therapeutics, Inc. | 17 Aug 2021 | 1 | +$10,238 | 4 | PRES./CHIEF SCIENTIFIC OFFICER | 18 Aug 2021, 18:20 |
| VTGN | VistaGen Therapeutics, Inc. | 30 Jun 2021 | 1 | +$6,601 | 4 | PRES./CHIEF SCIENTIFIC OFFICER | 02 Jul 2021, 16:10 |